The Role of Intravenous Selexipag in Managing PAH and Bridging Gaps in Oral Treatment: A Narrative R...
The Role of Intravenous Selexipag in Managing PAH and Bridging Gaps in Oral Treatment: A Narrative Review
About this item
Full title
Author / Creator
Publisher
New Zealand: Dove
Journal title
Language
English
Formats
Publication information
Publisher
New Zealand: Dove
Subjects
More information
Scope and Contents
Contents
Pulmonary arterial hypertension (PAH) is a rare and potentially fatal condition characterized by progressive increases in blood pressure in the arteries of the lungs. Oral selexipag, approved by the Food and Drug Administration (FDA) in 2015 for the treatment of PAH, targets prostacyclin receptors on pulmonary arterial vascular smooth muscle and en...
Alternative Titles
Full title
The Role of Intravenous Selexipag in Managing PAH and Bridging Gaps in Oral Treatment: A Narrative Review
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_ba5ab9cee10841f5bc7f5205af5633d0
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ba5ab9cee10841f5bc7f5205af5633d0
Other Identifiers
ISSN
1176-6336,1178-203X
E-ISSN
1178-203X
DOI
10.2147/TCRM.S332358
